Glenmark expects big growth from US: Glenn Saldanha

Glenmark expects big growth from US: Glenn Saldanha Glenmark Pharmaceuticals posted 48 per cent growth in net profit in the third quarter of FY16, but the result disappointed the Street, which was expecting more robust sales and profit growth. In an email interview with Aneesh Phadnis, the company’s chairperson, Glenn Saldanha, explains the reasons behind the poor performance. Edited excerpts: The third quarter result was disappointing as it came below Street estimates on both sales and profit figures. What went wrong? In major markets, on a constant currency basis, we have recorded a topline growth of 15-20 per cent. The Read More


ˆ Back To Top